NCT03009838

Brief Summary

Polycystic ovary syndrome is the major cause of anovulatory infertility. Clomiphene citrate is the most commonly used oral agent for ovulation induction in this group, but there are some drawbacks with the use of it.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
150

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Jan 2017

Longer than P75 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 1, 2017

Completed
1 day until next milestone

Study Start

First participant enrolled

January 2, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

January 4, 2017

Completed
5.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2022

Completed
8 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2023

Completed
Last Updated

May 9, 2022

Status Verified

May 1, 2022

Enrollment Period

5.9 years

First QC Date

January 1, 2017

Last Update Submit

May 6, 2022

Conditions

Outcome Measures

Primary Outcomes (1)

  • The ovulation rate

    3 months

Secondary Outcomes (1)

  • The mid-cyclic endometrial thickness

    one day

Study Arms (2)

letrozole

ACTIVE COMPARATOR

letrozole 2.5 mg oral tablets will be started daily from day 3 of the menses for 5 days in a dose of 5 mg/day

Drug: Letrozole

laparoscopic drilling

ACTIVE COMPARATOR

laparoscopy will be performed using three-puncture technique. Each ovary will be cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using a monopolar electrosurgical needle

Procedure: ovarian drilling

Interventions

oral tablets 2.5 mg

Also known as: femara
letrozole

laparoscopic electrocauterization

laparoscopic drilling

Eligibility Criteria

Age20 Years - 35 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • History of at least one year of infertility either primary or secondary.
  • Body mass index: 25-35
  • Normal fallopian tubes
  • Normal semen analysis of the husband
  • Women who will accept to participate in the study

You may not qualify if:

  • Body mass index above 35
  • Contraindication to general anesthesia
  • Previous laparoscopic drilling
  • Presence of other causes of infertility
  • Women who had received metformin, gonadotrophin, oral contraceptives or other hormonal drugs during the preceding 6 months
  • Women who intended to start a diet program
  • Women who will refuse to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University

Asyut, Egypt

RECRUITING

Related Publications (1)

  • Franik S, Le QK, Kremer JA, Kiesel L, Farquhar C. Aromatase inhibitors (letrozole) for ovulation induction in infertile women with polycystic ovary syndrome. Cochrane Database Syst Rev. 2022 Sep 27;9(9):CD010287. doi: 10.1002/14651858.CD010287.pub4.

MeSH Terms

Conditions

Infertility

Interventions

Letrozole

Condition Hierarchy (Ancestors)

Genital DiseasesUrogenital Diseases

Intervention Hierarchy (Ancestors)

NitrilesOrganic ChemicalsTriazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Central Study Contacts

Ahmed Abbas, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr.

Study Record Dates

First Submitted

January 1, 2017

First Posted

January 4, 2017

Study Start

January 2, 2017

Primary Completion

December 1, 2022

Study Completion

August 1, 2023

Last Updated

May 9, 2022

Record last verified: 2022-05

Data Sharing

IPD Sharing
Will share

Locations